5-HT2C receptor modulation and the treatment of obesity

被引：36
|
作者：
Bickerdike, MJ [1 ]
Vickers, SP [1 ]
Dourish, CT [1 ]
机构：
[1] Cerebrus PLC, Wokingham RG41 5UA, England
来源：
DIABETES OBESITY & METABOLISM | 1999年 / 1卷 / 04期
关键词：
D O I：
10.1046/j.1463-1326.1999.00037.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：207 / 214
页数：8
相关论文
共 50 条
  • [21] Synthesis and biological evaluation of novel, selective 5-HT2C receptor agonists for the treatment of obesity.
    Robichaud, AJ
    Chen, WT
    McClung, C
    Clark, D
    Deng, W
    Brondyke-Calvello, E
    Mitchell, IS
    Lee, TY
    Rajagopalan, P
    Fitzgerald, LW
    Conklin, DS
    McElroy, JF
    Rohrbach, KW
    Miller, KJ
    Largent, BL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U19 - U19
  • [22] 5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
    Przegalinski, Edmund
    Witek, Kacper
    Wydra, Karolina
    Kotlinska, Jolanta H.
    Filip, Malgorzata
    NUTRIENTS, 2023, 15 (06)
  • [23] A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment
    Palacios, Jose M.
    Pazos, Angel
    Hoyer, Daniel
    PSYCHOPHARMACOLOGY, 2017, 234 (9-10) : 1395 - 1418
  • [24] New 5-HT2c receptor agonists
    Bishop, MJ
    Nilsson, BM
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (11) : 1691 - 1705
  • [25] Imaging the 5-HT2C receptor with PET: Evaluation of 5-HT2C and 5-HT2A affinity of pimavanserin in the primate brain
    Ridler, Khanum
    Rizzo, Gaia
    Burstein, Ethan S.
    Forsberg Moren, Anton
    Stepanov, Vladimir
    Halldin, Christer
    Rabiner, Eugenii A.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2024,
  • [26] Evaluation of selective 5-HT2c phenylpiperazine agonists for the treatment of obesity.
    Tsai, JH
    Smith, BM
    Chen, R
    Prieto, E
    Park, D
    Smith, J
    Schultz, JA
    Gallardo, C
    Estrada, S
    Fang, S
    Gilson, C
    Thomsen, W
    Saldana, H
    Bjenning, C
    Creehan, K
    Gonzalez, L
    Whelan, K
    Webb, RR
    Beeley, N
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U113 - U113
  • [27] Chronic treatment with SSRIs desensitizes both 5-HT2A and 5-HT2C receptor function
    Yamauchi, Miki
    Miyara, Takako
    Matsushima, Tetsuya
    Tatebayashi, Tomoko
    Yokoyama, Fumikazu
    Onozawa, Kaname
    Yoshida, Akiko
    Imanishi, Taiichiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 101 : 84 - 84
  • [28] Synthesis and biological evaluation of novel, selective 5-HT2C receptor agonists for obesity
    Lee, T
    Robichaud, AJ
    Chen, WT
    Lu, YM
    Dowdell, S
    Boyle, KE
    Mitchell, IS
    Fevig, JM
    Wexler, RR
    Miller, KJ
    Largent, BL
    Rohrbach, KW
    Devenny, JJ
    McElroy, JF
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U158 - U159
  • [29] From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists
    Higgins, Guy A.
    Sellers, Edward M.
    Fletcher, Paul J.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2013, 34 (10) : 560 - 570
  • [30] Discovery and development of 5-HT2C receptor agonists for obesity: is there light at the end of the tunnel?
    Miller, Keith J.
    Wacker, Dean A.
    FUTURE MEDICINAL CHEMISTRY, 2010, 2 (12) : 1761 - 1775
12345